CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-07 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +75,409 | $9.53 | $719K | 106,511 |
| 2017-11-07 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −75,409 | $25.78 | $1.9M | 31,102 |
| 2017-11-07 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion · Stock Option | −75,409 | 300,000 | ||
| 2017-11-06 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion | +5,117 | $10.69 | $55K | 63,350 |
| 2017-11-06 | Hora Maninder SVP Pharma Dev & Mfg Ops | Sale | −5,117 | $25.07 | $128K | 58,233 |
| 2017-11-06 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion · Stock Option | −5,117 | 17,300 | ||
| 2017-11-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +20,914 | $9.53 | $199K | 52,016 |
| 2017-11-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −20,914 | $24.98 | $522K | 31,102 |
| 2017-11-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion · Stock Option | −20,914 | 375,409 | ||
| 2017-11-01 | ROBIN HOWARD W President & CEO | Exercise or conversion | +83,334 | $11.34 | $945K | 235,838 |
| 2017-11-01 | ROBIN HOWARD W President & CEO | Sale | −83,334 | $23.57 | $2.0M | 152,504 |
| 2017-11-01 | ROBIN HOWARD W President & CEO | Exercise or conversion · Stock Option | −83,334 | 166,666 | ||
| 2017-10-09 | ROBIN HOWARD W President & CEO | Exercise or conversion | +83,333 | $11.34 | $945K | 235,837 |
| 2017-10-09 | ROBIN HOWARD W President & CEO | Sale | −83,333 | $24.20 | $2.0M | 152,504 |
| 2017-10-09 | ROBIN HOWARD W President & CEO | Exercise or conversion · Stock Option | −83,333 | 250,000 | ||
| 2017-10-05 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion | +7,583 | $10.69 | $81K | 65,816 |
| 2017-10-05 | Hora Maninder SVP Pharma Dev & Mfg Ops | Sale | −7,583 | $25.00 | $190K | 58,233 |
| 2017-10-05 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion · Stock Option | −7,583 | 22,417 | ||
| 2017-10-05 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +43,677 | $9.53 | $416K | 74,779 |
| 2017-10-05 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −43,677 | $24.97 | $1.1M | 31,102 |
Page 39 of 43 · 847 trades